Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database
Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database
复制标题
DOI：
10.1200/jco.2014.55.1978
复制
发表时间：
2014-07-01
影响因子：
45.3
通讯作者：
Babiera, Gildy
中科院分区：
文献类型：
--
作者：
Rueth, Natasha M.;Lin, Heather Y.;Babiera, Gildy
目的 分析预测三联治疗（化疗、手术和放射治疗 [RT]）使用的因素，并评估三联治疗的使用对炎性乳腺癌 (IBC) 患者生存的影响。方法使用国家癌症数据库，确定 1998 年至 2010 年接受手术治疗非转移性 IBC 的患者。我们收集了人口统计、肿瘤和治疗数据，并分析了一段时间内的治疗和生存趋势。 Logistic 回归和 Cox 比例风险模型用于检查预测治疗和生存的因素。结果 我们确定了 10,197 名符合研究标准的患者。三联疗法的使用率每年都有波动（58.4% 至 73.4%）。年龄较大、在研究期间诊断较早、居住在中西部以外地区、收入或公共保险较低、合并症评分较高的患者接受三联疗法的可能性明显较小（所有 P
Purpose To analyze factors that predict the use of trimodality treatment (chemotherapy, surgery, and radiation therapy [RT]) and evaluate the impact that trimodality treatment use has on survival for patients with inflammatory breast cancer (IBC).Methods Using the National Cancer Data Base, patients who underwent surgical treatment of nonmetastatic IBC from 1998 to 2010 were identified. We collected demographic, tumor, and treatment data and analyzed treatment and survival trends over time. Logistic regression and Cox proportional hazard models were used to examine factors predicting treatment and survival.Results We identified 10,197 patients who fulfilled study criteria. The use of trimodality therapy fluctuated annually (58.4% to 73.4%). Patients who were older, diagnosed earlier in the study period, lived in regions of the country outside of the Midwest, had lower incomes or public insurance, and had a higher comorbid score were significantly less likely to receive trimodality therapy (all P